What compounds target MARK2?

BiohacksAI has identified 42 compounds that interact with MARK2 (microtubule affinity regulating kinase 2). Top compounds include: tofacitinib, tozasertib, ruxolitinib, doramapimod, midostaurin. Each compound is ranked by evidence score derived from PubMed bioassay confidence and assay count.

What is MARK2 (microtubule affinity regulating)?

MARK2 is microtubule affinity regulating kinase 2. It is a molecular target for 42 compounds documented in PubMed bioassay data. NCBI Gene ID: 2011.

MARK2

MOLECULAR TARGET

microtubule affinity regulating kinase 2

NCBI Gene: 201142 compounds

MARK2 (microtubule affinity regulating kinase 2) is targeted by 42 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting MARK2

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#	Compound	Confidence	Active Assays
1	tofacitinib	4.65	104
2	tozasertib	4.33	75
3	ruxolitinib	4.23	68
4	doramapimod	4.06	57
5	midostaurin	3.85	46
6	brigatinib	3.81	44
7	silmitasertib	3.78	43
8	nintedanib	3.61	36
9	baricitinib	3.56	34
10	tae 684	3.43	30
11	fedratinib	3.40	29
12	sp 600125	3.22	24
13	dovitinib	3.09	21
14	jnj 7706621	3.09	21
15	at 9283	3.09	21
16	lestaurtinib	3.04	20
17	pf 03758309	3.00	19
18	ruboxistaurin	2.94	18
19	danusertib	2.94	18
20	momelotinib	2.89	17
21	r 406	2.83	16
22	k 252a	2.83	16
23	milciclib	2.77	15
24	pf 00562271	2.77	15
25	pha 665752	2.71	14
26	crenolanib	2.71	14
27	kw 2449	2.64	13
28	gsk 690693	2.64	13
29	defactinib	2.48	11
30	ripasudil	2.40	10
31	azd 7762	2.30	9
32	bms 754807	2.30	9
33	su 014813	2.20	8
34	decernotinib	2.20	8
35	cyc 116	2.08	7
36	uprosertib	1.95	6
37	cerdulatinib	1.95	6
38	pf 03814735	1.79	5
39	ucn 01	1.79	5
40	alsterpaullone	0.69	1
41	kenpaullone	0.69	1
42	sp600125	0.69	1

About MARK2 as a Drug Target

MARK2 (microtubule affinity regulating kinase 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 42 compounds with documented MARK2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

MARK2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.